Literature DB >> 14526265

Comparative performance of serum cystatin-c versus serum creatinine in diabetic subjects.

M Buysschaert1, I Joudi, P Wallemacq, M P Hermans.   

Abstract

OBJECTIVE: Serum cystatin-C, a protein with constant production rate, undergoes glomerular filtration. Cystatin-C is a candidate surrogate marker, allegedly superior to serum creatinine, for estimating glomerular filtration rate, due to its high correlation with absolute measurement of the latter. The aim of this study was to assess from intra- and inter-subject variability the performance of cystatin-C in a cohort of diabetic patients spanning a wide range of kidney function and to compare it to that of serum creatinine. RESEARCH DESIGN AND METHODS: 98 consecutive diabetic in-patients (45 type 1 and 53 type 2) were included. Mean age was 53 +/- 15 years (1SD). Creatinine clearance was 98 ml/min (median; range: 16-244). We used the discriminant ratio (DR) methodology to compare the performance of serum cystatin-C vs. that of creatinine to segregate subjects according to their glomerular filtration rate.
RESULTS: Serum creatinine values on day 1 and 2 were 1.10 +/- 0.76 and 1.07 +/- 0.89 mg/dl and concentrations of cystatin-C were 1.10 +/- 0.60 and 1.06 +/- 0.63 mg/L. A close linear relationship was observed between means of duplicates for creatinine and cystatin-C (Pearson product-moment correlation 0.92). DR was obtained from the ratio of the underlying between-subject to the within-subject standard deviations. DR values were 5.23 for creatinine and 8.82 for cystatin-C (P<0.0001), implying superior discriminating ability for cystatin-C. Once adjusted for attenuation, measured Pearson product-moment correlation rose from 0.92 to 0.97. The DR methodology allowed for deriving an unbiased linear regression equation between methods, with slope and intercept at 0.79 and 0.23, respectively.
CONCLUSIONS: Serum cystatin-C better discriminates among a population of type 1 and 2 diabetic patients with regard to their estimated glomerular filtration rate when compared with conventional serum creatinine measurement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526265     DOI: 10.1016/s1262-3636(07)70048-4

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  5 in total

1.  Different association of cigarette smoking with GFR estimated from serum creatinine and that from serum cystatin C in the general population.

Authors:  Yuichi Yamada; Yuka Noborisaka; Masao Ishizaki; Michiko Yamazaki; Ryumon Honda; Hitoshi Yokoyama; Tatsuyuki Kakuma
Journal:  Clin Exp Nephrol       Date:  2014-11-19       Impact factor: 2.801

2.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study.

Authors:  Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

3.  Augmentation pressure and subendocardial viability ratio are associated with microalbuminuria and with poor renal function in type 1 diabetes.

Authors:  Catherine T Prince; Aaron M Secrest; Rachel H Mackey; Vincent C Arena; Lawrence A Kingsley; Trevor J Orchard
Journal:  Diab Vasc Dis Res       Date:  2010-07-06       Impact factor: 3.291

4.  Cystatin C-A novel marker of glomerular filtration rate: A review.

Authors:  Purnima Dey Sarkar; G Rajeshwari; T M Shivaprakash
Journal:  Indian J Clin Biochem       Date:  2005-01

5.  Estimated visceral adipose tissue, but not body mass index, is associated with reductions in glomerular filtration rate based on cystatin C in the early stages of chronic kidney disease.

Authors:  Ana Karina Teixeira da Cunha França; Alcione Miranda Dos Santos; João Victor Salgado; Elane Viana Hortegal; Antônio Augusto Moura da Silva; Natalino Salgado Filho
Journal:  Int J Nephrol       Date:  2014-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.